title: Subcutaneously administered apomorphine: pharmacokinetics and metabolism.
abstract: Apomorphine is a non-narcotic morphine derivative that acts as a potent dopaminergic agonist. Its high first-pass hepatic metabolism prevents effectiveness by the oral route; instead, subcutaneous injection is the usual route, and intranasal, sublingual, rectal, and iontophoretic transdermal delivery has been investigated for the treatment of Parkinson's disease (PD). The rate of uptake after subcutaneous injection is influenced by factors such as location, temperature, depth of injection, and body fat. Studies have shown the latency of onset to clinical effect after s.c. injection ranged from 7.3 to 14 minutes. Cerebrospinal fluid T(max)lags behind plasma T(max) by 10 to 20 minutes. Considerable intersubject variability is found with pharmacokinetic variables; in some studies there are five- to tenfold differences in C(max)and area-under-the-concentration-time-curve seen in PD patients. Apomorphine metabolism occurs through several enzymatic pathways, including N-demethylation, sulfation, glucuronidation, and catechol-O-methyltransferase as well as by nonenzymatic oxidation. The complexities of apomorphine uptake, distribution, and clearance probably contribute to its variability of clinical actions.
authors.affiliation: Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA.
authors.forename: Peter A
authors.initials: PA
authors.lastname: LeWitt
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics*; D001058:Apomorphine / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics*; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics*; D006801:Humans; D007279:Injections, Subcutaneous; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D001058:Apomorphine